Histoplasma capsulatum yeast phase-specific protein Yps3p induces Toll-like receptor 2 signaling

Journal of Neuroinflammation

Volumn 5, Issue , 2008, Pages

  Aravalli, Rajagopal N ^a   Hu, Shuxian ^a   Woods, Jon P ^b   Lokensgard, James R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGAL PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN YPS3P; TOLL LIKE RECEPTOR 2; LIGAND; PRIMER DNA;

ANIMAL CELL; ARTICLE; BRAIN CELL; CELL ISOLATION; CELL STRAIN HEK293; CELL WALL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; EMBRYO; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIGAND BINDING; MACROPHAGE; MICROGLIA; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VACCINIA VIRUS; WILD TYPE; YEAST; ANIMAL; C57BL MOUSE; GENETICS; HISTOPLASMA; MOLECULAR CLONING; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CLONING, MOLECULAR; DNA PRIMERS; FUNGAL PROTEINS; HISTOPLASMA; HISTOPLASMOSIS; HUMANS; LIGANDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2;

EID: 48249157326     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-5-30     Document Type: Article

References (45)

1. Anaissie E Fainstein V Samo T Bodey GP Sarosi GA Central nervous system histoplasmosis. An unappreciated complication of the acquired immunodeficiency syndrome Am J Med 1988, 84:215-217 10.1016/ 0002-9343(88)90416-0 3407651
2. Kauffman CA Histoplasmosis: A clinical and laboratory update Clin Microbiol Rev 2007, 20:115-132 1797635 17223625 10.1128/CMR.00027-06
3. Tan V Wilkins P Badve S Coppen M Lucas S Hay R Schon F Histoplasmosis of the central nervous system J Neurol Neurosurg Psychiatry 1992, 55:619-622 489178 1640242
4. Vos MJ Debets-Ossenkopp YJ Claessen FA Hazenberg GJ Heimans JJ Cerebellar and medullar histoplasmosis Neurology 2000, 54:1441 10798952
5. Walsh TJ Groll AH Emerging fungal pathogens: Evolving challenges to immunocompromised patients for the twenty-first century Transpl Infect Dis 1999, 1:247-261 10.1034/j.1399-3062.1999.010404.x 11428996
6. Haynes RR Connolly PA Durkin MM LeMonte AM Smedema ML Brizendine E Wheat LJ Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection J Infect Dis 2002, 185:1830-1832 10.1086/340825 12085335
7. LeMonte AM Washum KE Smedema ML Schnizlein-Bick C Kohler SM Wheat LJ Amphotericin B combined with itraconazole or fluconazole for treatment of histoplasmosis J Infect Dis 2000, 182:545-550 10.1086/315717 10915087
8. Wheat J Hafner R Korzun AH Limjoco MT Spencer P Larsen RA Hecht GFM Powderly W AIDS Clinical Trial Group Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome Am J Med 1995, 98:336-342 10.1016/ S0002-9343(99)80311-8 7709945
9. Knapp S Turnherr M Dekan G Willinger B Stingl G Rieger A A case of HIV-associated cerebral histoplasmosis successfully treated with fluconazole Eur J Clin Microbiol Infect Dis 1999, 18:658-661 10.1007/ s100960050368 10534189
10. Tiraboschi I Cases Parera I Pikielny R Scattini G Michell F Chronic Histoplasma capsulatum infection of the central nervous system successfully treated with fluconazole Eur Neurol 1992, 32:70-73 10.1159/ 000116794 1563464
11. Klein CJ Dinapoli RP Temesgen Z Meyer FB Central nervous system histoplasmosis mimicking a brain tumor: Difficulties in diagnosis and treatment Mayo Clin Proc 1999, 74:803-807 10473358
12. Voelker JL Muller J Worth RM Intermedullary spinal Histoplasma granuloma: Case report J Neurosurg 1989, 70:959-961 2715825
13. Keath EJ Painter AA Kobayashi GS Medoff G Variable expression of a yeast-phase-specific gene in Histoplasma capsulatum strains differing in thermotolerance and virulence Infect Immun 1989, 57:1384-1390 313287 2565289
14. Medoff G Sacco M Maresca B Schlessinger D Painter A Kobayashi GS Carratu L Irreversible block of the mycelial-to-yeast phase transition of Histoplasma capsulatum Science 1986, 231:476-479 10.1126/science.3001938 3001938
15. Eissenberg LG Goldman WE Schlesinger PH Histoplasma capsulatum modulates the acidification of phagolysosomes J Exp Med 1993, 177:1605-1611 2191039 8496679 10.1084/jem.177.6.1605
16. Eissenberg LG Schlesinger PH Goldman WE Phagosome-lysosome fusion in P388D1 macrophages infected with Histoplasma capsulatum J Leukoc Biol 1988, 43:483-491 2454277
17. Strasser JE Newman SL Ciraolo GM Morris RE Howell ML Dean GE Regulation of the macrophage vacuolar ATPase and phagosome-lysosome fusion by Histoplasma capsulatum J Immunol 1999, 162:6148-6154 10229858
18. Akira S Uematsu S Takeuchi O Pathogen recognition and innate immunity Cell 2006, 124:783-801 10.1016/j.cell.2006.02.015 16497588
19. Aravalli RN Peterson PK Lokensgard JR Toll-like receptors in defense and damage of the central nervous system J Neuroimmune Pharmacol 2007, 2:291-302 10.1007/s11481-007-9071-5
20. Aravalli RN Hu S Rowen TN Palmquist J Lokensgard JR Cutting Edge: TLR2-mediated production of proinflammatory cytokines and chemokines by microglial cells in response to herpes simplex virus J Immunol 2005, 175:4173-4189 16177057
21. Kielian T Esen N Bearden ED Toll-like receptor 2 (TLR2) is pivotal for recognition of S. aureus peptidoglycan but not intact bacteria by microglia Glia 2005, 49:567-576 2394509 15593098 10.1002/glia.20144
22. Kinsner A Boveri M Hareng L Brown GC Coecke S Hartung T Bal-Price A Highly purified lipoteichoic acid induced pro-inflammatory signalling in primary culture of rat microglia through Toll-like receptor 2: Selective potentiation of nitric oxide production by muramyl dipeptide J Neurochem 2006, 99:596-607 10.1111/j.1471-4159.2006.04085.x 16879708
23. Bellocchio S Montagnoli C Bozza S Gaziano R Rossi G Mambula SS Vecchi A Mantovani A Levitz SM Romani L The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo J Immunol 2004, 172:3059-3069 14978111
24. Biondo C Midiri A Messina L Tomasello F Garufi G Catania MR Bombaci M Beninati C Teti G Mancuso G MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans Eur J Immunol 2005, 35:870-878 10.1002/eji.200425799 15714580
25. Mambula SS Sau K Henneke P Golenbock DT Levitz SM Toll-like receptor [TLR] signaling in response to Aspergillus fumigatus J Biol Chem 2002, 277:39320-39326 10.1074/jbc.M201683200 12171914
26. Netea MG Sutmuller R Hermann C Graaf Van der CA Meer Van der JW van Krieken JH Hartung T Adema G Kullberg BJ Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells J Immunol 2004, 172:3712-3718 15004175
27. Netea MG Graaf Van Der CA Vonk AG Verschueren I Meer Van Der JW Kullberg BJ The role of toll-like receptor [TLR] 2 and TLR4 in the host defense against disseminated candidiasis J Infect Dis 2002, 185:1483-1489 10.1086/340511 11992285
28. Roeder A Kirschning CJ Schaller M Weindl G Wagner H Korting HC Rupec RA Induction of nuclear factor-kappaB and c-Jun/activator protein-1 via toll-like receptor 2 in macrophages by antimycotic-treated Candida albicans J Infect Dis 2004, 190:1318-1326 10.1086/423854 15346344
29. Tada H Nemoto E Shimauchi H Watanabe T Mikami T Matsumoto T Ohno N Tamura H Shibata K Akashi S Miyake K Sugawara S Takada H Saccharomyces cerevisiae - and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent manner Microbiol Immunol 2002, 46:503-512 12222939
30. Villamon E Gozalbo D Roig P O'Connor JE Fradelizi D Gil ML Toll-like receptor-2 is essential in murine defenses against Candida albicans infections Microbes Infect 2004, 6:1-7 10.1016/j.micinf.2003.09.020 14738887
31. Balloy V Si-Tahar M Takeuchi O Philippe B Nahori MA Tanguy M Huerre M Akira S Latge JP Chignard M Involvement of toll-like receptor 2 in experimental invasive pulmonary aspergillosis Infect Immun 2005, 73:5420-5425 1231150 16113258 10.1128/IAI.73.9.5420-5425.2005
32. Nakamura K Miyagi K Koguchi Y Kinjo Y Uezu K Kinjo T Akamine M Fujita J Kawamura I Mitsuyama M Adachi Y Ohno N Takeda K Akira S Miyazato A Kaku M Kawakami K Limited contribution of Toll-like receptor 2 and 4 to the host response to a fungal infectious pathogen, Cryptococcus neoformans FEMS Immunol Med Microbiol 2006, 47:148-154 10.1111/ j.1574-695X.2006.00078.x 16706798
33. Bohse ML Woods JP Surface localization of the Yps3p protein of Histoplasma capsulatum Eukaryot Cell 2005, 4:685-693 1087815 15821128 10.1128/EC.4.4.685-693.2005
34. Weaver CH Sheehan KC Keath EJ Localization of a yeast-phase-specific gene product to the cell wall in Histoplasma capsulatum Infect Immun 1996, 64:3048-3054 174186 8757832
35. Henderson HM Deepe GS Jr Recognition of Histoplasma capsulatum yeast-cell antigens by human lymphocytes and human T-cell clones J Leukoc Biol 1992, 51:432-436 1602236
36. Woods JP Heinecke EL Goldman WE Electrotransformation and expression of bacterial genes encoding hygromycin phosphotransferase and beta-galactosidase in the pathogenic fungus Histoplasma capsulatum Infect Immun 1998, 66:1697-1707 108107 9529100
37. Fisher KL Woods JP Determination of β-glucosidase enzymatic function of the Histoplasma capsulatum H antigen using a native expression system Gene 2000, 247:191-197 10.1016/S0378-1119(00)00099-8 10773459
38. Chao CC Molitor TW Hu S Neuroprotective role of IL-4 against activated microglia J Immunol 1993, 151:1473-1481 8335941
39. Aravalli RN Hu S Lokensgard JR Inhibition of Toll-like receptor signaling in primary murine microglia J Neuroimmune Pharmacol 2008, 3:5-11 10.1007/s11481-007-9097-8 18066668
40. Jouault T Ibata-Ombetta S Takeuchi O Trinel PA Sacchetti P Lefebvre P Akira S Poulain D Candida albicans phospholipomannan is sensed through toll-like receptors J Infect Dis 2003, 188:165-172 10.1086/375784 12825186
41. Bowie A Kiss-Toth E Symons JA Smith GL Dower SK O'Neill LA A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling Proc Natl Acad Sci USA 2000, 97:10162-10167 27775 10920188 10.1073/pnas.160027697
42. Harte MT Haga IR Maloney G Gray P Reading PC Bartlett NW Smith GL Bowie A O'Neill LA The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense J Exp Med 2003, 197:343-351 2193841 12566418 10.1084/jem.20021652
43. DiPerna G Stack J Bowie AG Boyd A Kotwal G Zhang Z Arvikar S Latz E Fitzgerald KA Marshall WL Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors J Biol Chem 2004, 279:36570-36578 10.1074/jbc.M400567200 15215253
44. Shisler JL Jin XL The vaccinia virus K1L gene product inhibits host NF-κB activation by preventing IκBα degradation J Virol 2004, 78:3553-3560 371086 15016878 10.1128/JVI.78.7.3553-3560.2004
45. Meier A Kirschning CJ Nikolaus T Wagner H Heesemann J Ebel F Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages Cell Microbiol 2003, 5:561-570 10.1046/ j.1462-5822.2003.00301.x 12864815